RoB 2: a revised tool for assessing risk of bias in randomised trials
…, HY Cheng, MS Corbett, SM Eldridge, JR Emberson… - bmj, 2019 - bmj.com
Assessment of risk of bias is regarded as an essential component of a systematic review on
the effects of an intervention. The most commonly used tool for randomised trials is the …
the effects of an intervention. The most commonly used tool for randomised trials is the …
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised …
Objective To assess the effects of selective cyclo-oxygenase-2 (COX 2) inhibitors and traditional
non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of vascular events. Design …
non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of vascular events. Design …
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate
…, BK Mahmoodi, M Woodward, JR Emberson… - Jama, 2012 - jamanetwork.com
Context The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation more
accurately estimates glomerular filtration rate (GFR) than the Modification of Diet in Renal …
accurately estimates glomerular filtration rate (GFR) than the Modification of Diet in Renal …
[HTML][HTML] COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England
…, T Denwood, MJ Landray, JR Emberson, R Collins… - The Lancet, 2020 - thelancet.com
Background Several countries affected by the COVID-19 pandemic have reported a substantial
drop in the number of patients attending the emergency department with acute coronary …
drop in the number of patients attending the emergency department with acute coronary …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
…, G Pessoa-Amorim, E Spata, N Staplin, JR Emberson… - Medrxiv, 2021 - medrxiv.org
Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 …
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 …
Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity
…, J Alegre-Díaz, JM Torres, JR Emberson, R Collins… - Science, 2021 - science.org
INTRODUCTION Obesity accounts for a substantial and growing burden of disease globally.
Body adiposity is highly heritable, and human genetic studies can lead to biological and …
Body adiposity is highly heritable, and human genetic studies can lead to biological and …
Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement
PH Whincup, JA Gilg, JR Emberson, MJ Jarvis… - Bmj, 2004 - bmj.com
Objective To examine the associations between a biomarker of overall passive exposure to
tobacco smoke (serum cotinine concentration) and risk of coronary heart disease and stroke. …
tobacco smoke (serum cotinine concentration) and risk of coronary heart disease and stroke. …
Is the association between parity and coronary heart disease due to biological effects of pregnancy or adverse lifestyle risk factors associated with child-rearing …
DA Lawlor, JR Emberson, S Ebrahim, PH Whincup… - Circulation, 2003 - Am Heart Assoc
Background— Parity is associated with coronary heart disease (CHD) risk. In the present
study, we assessed the associations between number of children and CHD in both women and …
study, we assessed the associations between number of children and CHD in both women and …
[HTML][HTML] Diabetes and cause-specific mortality in Mexico City
…, R Peto, P Kuri-Morales, JR Emberson - … England Journal of …, 2016 - Mass Medical Soc
Background Most large, prospective studies of the effects of diabetes on mortality have focused
on high-income countries where patients have access to reasonably good medical care …
on high-income countries where patients have access to reasonably good medical care …
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
…, PW Horby, L Estcourt, L Peto, JR Emberson… - MedRxiv, 2021 - medrxiv.org
Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the safety …
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the safety …